Journal article · 2026 · Open access

Protacs in oncology: Emerging frontiers in targeted protein degradation

Vipin Kumar Gautam, Abhishek Meshram, Naveen Telu, Amrendra Pratap, Shivam .

International Journal of Advanced Biochemistry Research, 10(8S), 399–408 · Published 1 August 2026 · DOI 10.33545/26174693.2026.v10.i8se.9457

Open PDFView at the publisherCite this paper

In brief

“Protacs in oncology: Emerging frontiers in targeted protein degradation” is a 2026 journal article by Vipin Kumar Gautam and 4 co-authors, published in International Journal of Advanced Biochemistry Research. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at International Journal of Advanced Biochemistry Research.

Citations
0
References
45
Authors
5

Abstract

Cancer remains a major global health challenge, with rising incidence and mortality despite significant advances in diagnosis and treatment. Conventional therapeutic approaches are often limited by drug resistance, off-target toxicity, and the inability to effectively target many disease-associated proteins. Proteolysis-Targeting Chimeras (PROTACs) have emerged as a novel and transformative strategy in targeted protein degradation, utilizing the ubiquitin–proteasome system to selectively eliminate pathogenic proteins. Since their introduction in 2001, PROTACs have evolved from peptide-based molecules to highly efficient small-molecule and next-generation degraders, demonstrating broad applicability in oncology. Their catalytic mode of action enables degradation of oncogenic proteins, including previously “undruggable” targets such as BRD4, CDK4/6, EGFR, AURORA-A, and BRAF. Several PROTAC candidates, including ARV-110, ARV-471, ARV-766, NX-2127, and KT-474, have advanced into clinical trials, highlighting their therapeutic potential across multiple malignancies. Furthermore, innovations such as PHOTACs, NanoPDs, and antibody-based degraders are expanding the scope and precision of targeted protein degradation. Despite challenges related to pharmacokinetics, target selection, and resistance mechanisms, ongoing advancements in PROTAC design and delivery continue to accelerate their clinical translation. This review summarizes the historical development, mechanisms of action, clinical progress, therapeutic applications, challenges, and future prospects of PROTAC technology, emphasizing its potential to redefine precision oncology and next-generation cancer therapeutics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gautam, V. K., Meshram, A., Telu, N., Pratap, A., & ., S. (2026). Protacs in oncology: Emerging frontiers in targeted protein degradation. International Journal of Advanced Biochemistry Research, 10(8S), 399–408. https://doi.org/10.33545/26174693.2026.v10.i8se.9457

MLA 9

Gautam, Vipin Kumar, et al. “Protacs in oncology: Emerging frontiers in targeted protein degradation.” International Journal of Advanced Biochemistry Research, vol. 10, no. 8S, 2026, pp. 399–408. https://doi.org/10.33545/26174693.2026.v10.i8se.9457.

Chicago

Gautam, Vipin Kumar, Abhishek Meshram, Naveen Telu, Amrendra Pratap, and Shivam . 2026. “Protacs in oncology: Emerging frontiers in targeted protein degradation.” International Journal of Advanced Biochemistry Research 10 (8S): 399–408. https://doi.org/10.33545/26174693.2026.v10.i8se.9457.

Harvard

Gautam, V. K. et al. (2026) ‘Protacs in oncology: Emerging frontiers in targeted protein degradation’, International Journal of Advanced Biochemistry Research, 10(8S), pp. 399–408. doi:10.33545/26174693.2026.v10.i8se.9457.

IEEE

V. K. Gautam, A. Meshram, N. Telu, A. Pratap, and S. ., “Protacs in oncology: Emerging frontiers in targeted protein degradation,” International Journal of Advanced Biochemistry Research, vol. 10, no. 8S, pp. 399–408, 2026, doi: 10.33545/26174693.2026.v10.i8se.9457.

BibTeX

@article{gautam2026protacs,
  title     = {{Protacs in oncology: Emerging frontiers in targeted protein degradation}},
  author    = {Gautam, Vipin Kumar and Meshram, Abhishek and Telu, Naveen and Pratap, Amrendra and ., Shivam},
  journal   = {International Journal of Advanced Biochemistry Research},
  year      = {2026},
  volume    = {10},
  number    = {8S},
  pages     = {399--408},
  doi       = {10.33545/26174693.2026.v10.i8se.9457},
  url       = {https://doi.org/10.33545/26174693.2026.v10.i8se.9457}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • ubiquitin-proteasome system
  • cancer therapeutics
  • undruggable targets
  • BRD4
  • CDK4/6
  • EGFR

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Gautam, V. K., Meshram, A., Telu, N., Pratap, A., & ., S. (2026). Protacs in oncology: Emerging frontiers in targeted protein degradation. International Journal of Advanced Biochemistry Research, 10(8S), 399–408. https://doi.org/10.33545/26174693.2026.v10.i8se.9457

How many times has this paper been cited?

0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at International Journal of Advanced Biochemistry Research: sign in and open the PDF from this page.

Who wrote this paper?

Vipin Kumar Gautam, Abhishek Meshram, Naveen Telu, Amrendra Pratap, Shivam ..

What is the DOI of this paper?

10.33545/26174693.2026.v10.i8se.9457, permanently at https://doi.org/10.33545/26174693.2026.v10.i8se.9457. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.